PMID- 20009917 OWN - NLM STAT- MEDLINE DCOM- 20110110 LR - 20220317 IS - 1473-5571 (Electronic) IS - 0269-9370 (Linking) VI - 24 IP - 3 DP - 2010 Jan 28 TI - Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. PG - F1-9 LID - 10.1097/QAD.0b013e32833562c5 [doi] AB - OBJECTIVE: To assess the effects of initiating abacavir-containing therapy on plasma lipids and cardiovascular biomarkers. DESIGN: Sub-study of the BICOMBO study in which participants were randomized to switch their nucleoside backbone to either abacavir/lamivudine or tenofovir/emtricitabine. METHODS: We assessed 48-week changes in fasting lipids and several biomarkers including serum high-sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein-1 (MCP-1), osteoprotegerin, interleukin (IL)-6, IL-10, tumor necrosis factor alpha (TNF-alpha), intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), selectin E and P, adiponectin, insulin, and D-dimer in otherwise healthy, virologically suppressed HIV-infected patients randomly switched to abacavir/lamivudine or tenofovir/emtricitabine with no history of cardiovascular disease, no prior abacavir or tenofovir use, and no virological failure or AIDS during follow-up. RESULTS: Eighty (46 abacavir/lamivudine and 34 tenofovir/emtricitabine) patients were included. Baseline characteristics were similar between groups and between patients in the sub-study vs. those not. There were no significant differences in baseline lipids and markers between groups. Although total (6.5 vs. -6.7%, P < 0.0001) and low-density lipoprotein (LDL) (8.6 vs. -9.1%, P = 0.004) cholesterol increased significantly in the abacavir/lamivudine group relative to the tenofovir/emtricitabine group, we found no significant changes in the biomarkers: CRP (-3.9 vs. 0.0%), MCP-1 (5.9 vs. 4.0%), osteoprotegerin (5.1 vs. -2.8%), IL-6 (0.0 vs. 0.0%), IL-10 (0.0 vs. 0.0%), TNF-alpha (0.0 vs. 0.0%), ICAM-1 (6.6 vs. 5.2%), VCAM-1 (0.02 vs. -0.01%), selectin E (-0.4 vs. 7.8%), selectin P (4.6 vs. 12.6%), insulin (-2.5 vs. 8.8%), adiponectin (-2.2 vs. 15.4%), and D-dimer (0.0 vs. 0.0%) (P > or = 0.12 for all comparisons). CONCLUSION: Abacavir/lamivudine increased total and LDL cholesterol compared with tenofovir/emtricitabine, but it did not cause inflammation, endothelial dysfunction, insulin resistance, or hypercoagulability in virologically suppressed HIV-infected patients. FAU - Martinez, Esteban AU - Martinez E AD - Infectious Diseases Unit, Hospital Clinic-Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C/Villarroel 170, 08036 Barcelona, Spain. esteban@fundsoriano.es FAU - Larrousse, Maria AU - Larrousse M FAU - Podzamczer, Daniel AU - Podzamczer D FAU - Perez, Ignacio AU - Perez I FAU - Gutierrez, Felix AU - Gutierrez F FAU - Lonca, Montserrat AU - Lonca M FAU - Barragan, Patricia AU - Barragan P FAU - Deulofeu, Ramon AU - Deulofeu R FAU - Casamitjana, Roser AU - Casamitjana R FAU - Mallolas, Josep AU - Mallolas J FAU - Pich, Judit AU - Pich J FAU - Gatell, Jose M AU - Gatell JM CN - BICOMBO Study Team LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - England TA - AIDS JT - AIDS (London, England) JID - 8710219 RN - 0 (Anti-HIV Agents) RN - 0 (Biomarkers) RN - 0 (Dideoxynucleosides) RN - 0 (Lipids) RN - 0 (Organophosphonates) RN - 0 (Reverse Transcriptase Inhibitors) RN - 0W860991D6 (Deoxycytidine) RN - 2T8Q726O95 (Lamivudine) RN - 99YXE507IL (Tenofovir) RN - G70B4ETF4S (Emtricitabine) RN - JAC85A2161 (Adenine) RN - WR2TIP26VS (abacavir) SB - IM MH - Adenine/administration & dosage/analogs & derivatives MH - Adult MH - Anti-HIV Agents/*administration & dosage/adverse effects MH - Biomarkers/blood MH - Cardiovascular Diseases/*blood MH - Deoxycytidine/administration & dosage/analogs & derivatives MH - Dideoxynucleosides/*administration & dosage/adverse effects MH - Drug Therapy, Combination MH - Emtricitabine MH - Female MH - HIV Infections/blood/*drug therapy/virology MH - *HIV-1 MH - Humans MH - Lamivudine/administration & dosage MH - Lipids/blood MH - Male MH - Middle Aged MH - Organophosphonates/administration & dosage MH - Reverse Transcriptase Inhibitors/*administration & dosage/adverse effects MH - Tenofovir MH - Treatment Outcome MH - Viral Load FIR - Barragan, Patricia IR - Barragan P FIR - Ferrer, Elena IR - Ferrer E FIR - Iniguez, Daniel IR - Iniguez D FIR - Leibenger, Gabriela IR - Leibenger G FIR - Podzamczer, Daniel IR - Podzamczer D FIR - Arnedo, Mireia IR - Arnedo M FIR - Blanco, Jose L IR - Blanco JL FIR - Calvo, Marta IR - Calvo M FIR - Gatell, Jose M IR - Gatell J FIR - Laguno, Montserrat IR - Laguno M FIR - Larrousse, Maria IR - Larrousse M FIR - Leon, Agathe IR - Leon A FIR - Lonca, Montserrat IR - Lonca M FIR - Mallolas, Josep IR - Mallolas J FIR - Martinez, Esteban IR - Martinez E FIR - Martinez-Rebollar, Maria IR - Martinez-Rebollar M FIR - Milinkovic, Ana IR - Milinkovic A FIR - Miro, Jose M IR - Miro JM FIR - Moreno, Xabier IR - Moreno X FIR - Pumarola, Tomas IR - Pumarola T FIR - Fuster, Monica IR - Fuster M FIR - Roca, Victor IR - Roca V FIR - Bernal, Enrique IR - Bernal E FIR - Gutierrez, Felix IR - Gutierrez F FIR - Masia, Mar IR - Masia M FIR - Padilla, Sergio IR - Padilla S FIR - Bravo, Isabel IR - Bravo I FIR - Clotet, Bonaventura IR - Clotet B FIR - Echeverria, Patricia IR - Echeverria P FIR - Berenguer, Juan IR - Berenguer J FIR - Cosin, Jaime IR - Cosin J FIR - Gutierrez, Isabel IR - Gutierrez I FIR - Ramirez, Margarita IR - Ramirez M FIR - Sanchez, Matilde IR - Sanchez M FIR - Peraire, Joaquim IR - Peraire J FIR - Vidal, Francesc IR - Vidal F FIR - Knobel, Hernando IR - Knobel H FIR - Gonzalez, Alicia IR - Gonzalez A FIR - Force, Luis IR - Force L FIR - Barrufet, Pilar IR - Barrufet P FIR - Cairo, Mireia IR - Cairo M FIR - Dalmau, David IR - Dalmau D FIR - Garcia, Carol IR - Garcia C FIR - Anton, Esperanza IR - Anton E FIR - Penelo, Eva IR - Penelo E FIR - Segura, Ferran IR - Segura F FIR - Arribas, Jose R IR - Arribas JR FIR - Castro, Juan Miguel IR - Castro JM FIR - Montes, Maria IR - Montes M FIR - Carrillo, Raquel IR - Carrillo R FIR - de los Santos, Ignacio IR - de los Santos I FIR - Arranz, Jose A IR - Arranz JA FIR - Casas, Esperanza IR - Casas E FIR - de Miguel, Julio IR - de Miguel J FIR - Sanz, Jose IR - Sanz J FIR - Llibre, Josep M IR - Llibre JM FIR - Valero, Silvia IR - Valero S FIR - Payeras, Antoni IR - Payeras A FIR - Galo, Francisco IR - Galo F FIR - Ribera, Esteban IR - Ribera E FIR - Curran, Adria IR - Curran A EDAT- 2009/12/17 06:00 MHDA- 2011/01/11 06:00 CRDT- 2009/12/17 06:00 PHST- 2009/12/17 06:00 [entrez] PHST- 2009/12/17 06:00 [pubmed] PHST- 2011/01/11 06:00 [medline] AID - 10.1097/QAD.0b013e32833562c5 [doi] PST - ppublish SO - AIDS. 2010 Jan 28;24(3):F1-9. doi: 10.1097/QAD.0b013e32833562c5.